Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaratumab Biomarker Study in Soft Tissue Sarcoma
NCT02783599Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2016
- Primary completion
- Jul 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of olaratumab in soft tissue sarcoma (STS) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percent Change From Baseline in Enumeration of Circulating Tumor Cells, Percent Change From Baseline in Gene Expression of PDGFR-alpha and PDGFR-beta and 1 more. Started Oct 2016; status: completed.
02
Drugs
olaratumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02783599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02783599.